Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LPP
REST API REST API
Homo sapiens
LPP is differentially expressed in 357 experiments: 177 organism parts: prostate, brain, ... (175 more);, 257 disease states: normal, colon carcinoma, ... (255 more);, 117 cell types 486 cell lines 48 compound treatments and 82 other conditions.
Orthologs LPP_CHICK (Gallus gallus)   lpp (Danio rerio)   Lpp (Mus musculus)   ENSCING00000006648 (Ciona intestinalis)   LPP_RAT (Rattus norvegicus)   LPP (Bos taurus)   Zyx102EF (Drosophila melanogaster)   lpp (Xenopus laevis)   LPP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, plasma membrane, protein binding, cytoplasm, metal ion binding, cell junction, biological_process, cell adhesion, nucleus, zinc ion binding
InterPro Term Znf_LIM
UniProt Accession C9J1K7, C9J2R5, C9J3U9, C9J4E3, Q93052, C9J5C8, C9JE51, C9JIY7, C9JT42, B7Z871, C9JUT4, C9JXK9
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000145012
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SNU1
2
E-GEOD-15460, E-MTAB-37
Jurkat
2
E-MEXP-2197, E-GEOD-1880
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-5823, E-GEOD-3529
480 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (54 experiments)

Factor Value U/D Experiments
embryonic stem cell
3
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
2
2
E-TABM-130, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
mononuclear
2
E-GEOD-13987, E-GEOD-26672
testis - germ cell
2
E-AFMX-5, E-TABM-145
monocyte
1
2
E-MEXP-583, E-GEOD-11755, E-GEOD-22373
111 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MEXP-2280, ... (74 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-3726, E-MTAB-57
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-995, E-GEOD-1729
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-TABM-26
dermatomyositis
2
E-GEOD-5370, E-MTAB-62
juvenile dermatomyositis
2
E-GEOD-3307, E-MTAB-62
251 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (32 experiments)

Factor Value U/D Experiments
none
5
10
E-MEXP-1958, E-MEXP-1230, E-GEOD-412, E-GEOD-5824, E-MEXP-1389, ... (15 experiments)
nocodazole
1
E-GEOD-571
bicalutamide and dihydrotestoterone
1
E-GEOD-7708
anti-CD3 + anti-CD28
1
E-GEOD-7307
N-nitrosodimethylamine
1
E-GEOD-6907
unknown
1
E-GEOD-7307
42 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-1059, E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-21612, E-GEOD-20540, E-GEOD-10315, E-TABM-440, E-TABM-263, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-26, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-26495, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.404 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM